Lumexa Imaging Holdings Q3 2026 earnings

LMRI · 2026-11-10 16:05 AMC ET · 8-K on SEC

Revenue and Adjusted EBITDA grew, while GAAP net income improved from a loss to a profit driven by lower interest expense and a lower tax rate.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)$0.07+140.0%+133.3%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Net patient service revenue$211.12M+4.7%77.6%—
Management fee and other revenue$60.86M+6.3%22.4%—

Margins and costs

  • Gross margin 15.2% (prior 15.2%, change 0.0 pp)
  • Operating expenses $266.71M (+9.1% YoY)
  • One-offs in the quarter Fair market value adjustment on debt $654k; Transaction costs ($661k); Litigation and settlements $3.58M; Strategic initiatives and implementation $2.37M; Severance and executive recruiting $622k
  • Effective tax rate 39.1% (prior-year 39.1%, year-to-date 43.5%)
  • Non-GAAP bridge Adds back stock-based compensation, transaction costs, litigation, strategic initiatives, severance, fair market value adjustment, and amortization of basis difference; equity in earnings of unconsolidated affiliates are also adjusted.

KPIs

MetricActualPrior quarterPrior yearChange
Advanced ProceduresRecord high———
Center count190 total———
Cash and cash equivalents$90.01M$69.71M$4.75M+29.1%

Guidance

MetricGuidePrior guideChange
Total revenues$1.025B - $1.045B$1.025B - $1.045B—
Adjusted EBITDA$235M - $245M$235M - $245M—
Adjusted EPS$0.23 - $0.24$0.23 - $0.24—

What drove it

  • Revenue story Net patient service revenue grew 4.7% and management fees grew 6.3% year-over-year.
  • EPS story EPS improved due to a lower tax rate and a narrower loss in prior-year periods, rather than revenue growth.
  • One-off check Fair market value adjustment on debt $654k; Transaction costs ($661k); Litigation and settlements $3.58M; Strategic initiatives and implementation $2.37M; Severance and executive recruiting $622k.

The good

  • Adjusted EBITDA margin expanded 2.4 pp sequentially to 23.0%
  • Cash and cash equivalents increased 29.1% to $90.01M

The bad

  • Net patient service revenue growth slowed to 4.7% from 5.1% in Q2
  • Interest expense remains high at $15.67M

The ugly

  • none

Open questions

  • What is the specific amount of the fair market value adjustment on debt?
  • What is the breakdown of the $3.58M litigation and settlements charge?
  • What is the specific amount of the $2.37M strategic initiatives and implementation charge?
Full release

Lumexa Imaging Holdings (LMRI) earnings release, November 10, 2026

Lumexa Imaging Holdings, Inc. (LMRI) · Form 8-K, Item 2.02 · Filed · SEC filing

Lumexa Imaging Announces Third Quarter 2026 Results

RALEIGH, N. C., November 10, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026.

“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “These achievements mark progress toward our long-term growth plans, and that progress is translating into strong, durable cash generation. We enter the fourth quarter confident in our ability to deliver for patients, partners, and shareholders.”

“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”

Third Quarter 2026 Highlights

All comparisons are to the quarter ended September 30, 2025, unless otherwise noted

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its third quarter 2026 results on November 10, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of

Non-GAAP

Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and

Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance;

(ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and approximately 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
REVENUES:
Net patient service revenue211,115201,695
Management fee and other revenue60,85857,249
Total revenues271,973258,944
OPERATING EXPENSES:
Cost of operations, excluding depreciation and amortization225,571219,236
General and administrative expenses30,02517,081
Depreciation and amortization10,3319,654
Loss on disposal of property and equipment779623
Total operating expenses266,706246,594
Equity in earnings of unconsolidated affiliates22,84617,990
INCOME FROM OPERATIONS28,11330,340
OTHER EXPENSES:
Interest expense15,67430,577
Fair market value adjustment on debt654
Total other expenses16,32830,577
INCOME (LOSS) BEFORE INCOME TAXES11,785-237
Income tax provision4,6073,264
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)7,178-3,501
Weighted average shares outstanding:
Basic95,983,24669,531,530
Diluted96,256,07769,531,530
Net income (loss) per common share
Basic0.07-0.05
Diluted0.07-0.05

Income Statement

Nine Months Ended September 30, — (Unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
REVENUES:
Net patient service revenue612,168592,178
Management fee and other revenue176,504163,169
Total revenues788,672755,347
OPERATING EXPENSES:
Cost of operations, excluding depreciation and amortization668,611639,898
General and administrative expenses74,75753,262
Depreciation and amortization30,33627,984
Loss on disposal of property and equipment892477
Total operating expenses774,596721,621
Equity in earnings of unconsolidated affiliates56,48949,835
INCOME FROM OPERATIONS70,56583,561
OTHER EXPENSES:
Interest expense48,22790,523
Loss on extinguishment and modification of debt1,053
Fair market value adjustment on debt654
Total other expenses49,93490,523
INCOME (LOSS) BEFORE INCOME TAXES20,631-6,962
Income tax provision8,99111,452
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)11,640-18,414
Weighted average shares outstanding:
Basic95,983,24269,527,181
Diluted96,092,91669,527,181
Net income (loss) per common share
Basic0.12-0.26
Diluted0.12-0.26

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Net income (loss)7,178-3,501
Depreciation and amortization10,3319,654
Income tax provision4,6073,264
Amortization of basis difference573500
Interest expense15,67430,577
Stock-based compensation12,3398,312
Loss on disposal of property and equipment779623
Fair market value adjustment on debt654
Severance and executive recruiting(1)622365
Strategic initiatives and implementation(2)2,3651,198
Transaction costs(3)-6612,899
Litigation and settlements(4)3,578-14
Other(5)362728
Adjustments for equity in earnings of unconsolidated affiliates(6)4,1944,525
Adjusted EBITDA62,59559,130

Income Statement

Nine Months Ended September 30, — (Unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)11,640-18,414
Depreciation and amortization30,33627,984
Income tax provision8,99111,452
Amortization of basis difference1,6781,500
Interest expense48,22790,523
Stock-based compensation37,35023,032
Loss on extinguishment and modification of debt1,053
Loss on disposal of property and equipment892477
Fair market value adjustment on debt654
Severance and executive recruiting(1)2,2532,538
Strategic initiatives and implementation(2)5,8493,084
Transaction costs(3)2,62810,363
Litigation and settlements(4)4,780-142
Other(5)444886
Adjustments for equity in earnings of unconsolidated affiliates(6)13,46413,121
Adjusted EBITDA170,239166,404

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Nine Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2025
Components of “management fee and other revenues:”
Fees for managing joint ventured outpatient sites and other third party services25,88923,843
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa34,96933,406
Total revenues60,85857,249
Fees for managing joint ventured outpatient sites and other third party services73,49064,497
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa103,01498,672
Total revenues176,504163,169

Balance Sheet

September 30, 2026 — (Unaudited) (in thousands)

September 30, 2026December 31, 2025
ASSETS
Cash and cash equivalents90,01158,828
Accounts receivable117,769112,942
Accounts receivable, related party22,57018,893
Other receivables33,17419,015
Prepaid expenses14,78917,582
Total current assets278,313227,260
Property and equipment, net of accumulated depreciation158,847144,709
Operating lease right-of-use assets74,83376,555
Investments in unconsolidated affiliates428,019423,191
Intangible assets, net of accumulated amortization38,58241,335
Goodwill807,554807,554
Other assets46,98843,953
TOTAL ASSETS1,833,1361,764,557
LIABILITIES AND EQUITY
Accounts payable20,38244,857
Accrued expenses and other current liabilities117,92095,561
Accounts receivable pledging arrangement2,3221,599
Current portion of long-term debt15,54813,112
Current portion of finance lease liabilities15,00711,552
Current portion of operating lease liabilities12,27712,513
Total current liabilities183,456179,194
Long-term debt, less current maturities821,524819,029
Long-term finance lease liabilities, less current maturities39,78233,262
Long-term operating lease liabilities, less current maturities70,37771,437
Deferred income taxes47,04440,772
Other liabilities36,87034,740
Total liabilities1,199,0531,178,434
EQUITY:
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,062,177 shares issued and outstanding at September 30, 2026 and 96,109,927 shares issued and outstanding at December 31, 20259696
Additional paid-in-capital1,253,4071,217,087
Accumulated deficit-619,420-631,060
Total equity634,083586,123
TOTAL LIABILITIES AND EQUITY1,833,1361,764,557

Cash Flow

Nine Months Ended September 30, — (Unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)11,640-18,414
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization30,33627,984
Amortization of operating lease right-of-use assets11,87911,162
Amortization of debt issuance costs2,1614,337
Amortization of cloud computing implementation costs1,332271
Unrealized fair market value adjustment on debt263
Write-off of debt issuance costs related to extinguishment of debt46
Equity in earnings of unconsolidated affiliates-56,489-49,835
Distributions from investments in unconsolidated affiliates55,02841,223
Loss on disposal of property and equipment892477
Deferred income taxes6,2723,502
Stock-based compensation37,35023,032
Other-1,030
Changes in operating assets and liabilities:
Accounts receivable-4,827-7,206
Accounts receivable, related party-3,6772,189
Capitalized cloud computing implementation costs-2,773-1,686
Other receivables-14,159-7,494
Prepaid expenses2,094-6,369
Other assets-2,196-15,418
Accounts payable-24,4755,007
Accrued expenses and other current liabilities29,725-10,889
Other liabilities2,6057,700
Operating lease liabilities-11,453-9,602
Net cash provided by (used in) operating activities70,544-29
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale or disposal of property and equipment196794

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,”

“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”

“should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; and our ability to drive future growth and execute on our goals and strategies. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form

10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form

10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact

Sue Dooley

Lumexa Imaging

Sue.Dooley@LumexaImaging.com

Media Contact elissa Weston

Lumexa Imaging

Melissa.Weston@LumexaImaging.com

Lumexa Imaging Q3 2026 Outpatient Volumes Highlights:

Note: Advanced Procedures includes MRI and CT modalities. As of September 30, 2026 Center count was 190 total, 87 JV and 103 consolidated.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lumexa Imaging Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.